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Abstract 
Background: The efficacy and safety of high flow nasal therapy (HFNT) in patients with acute hypercapnic exacerba-
tion of chronic obstructive pulmonary disease (AECOPD) are unclear. Our aim was to evaluate the short-term effect of 
HFNT versus NIV in patients with mild-to-moderate AECOPD, with the hypothesis that HFNT is non-inferior to NIV on 
 CO2 clearance after 2 h of treatment.
Methods: We performed a multicenter, non-inferiority randomized trial comparing HFNT and noninvasive ventilation 
(NIV) in nine centers in Italy. Patients were eligible if presented with mild-to-moderate AECOPD (arterial pH 7.25–7.35, 
 PaCO2 ≥ 55 mmHg before ventilator support). Primary endpoint was the mean difference of  PaCO2 from baseline to 
2 h (non-inferiority margin 10 mmHg) in the per-protocol analysis. Main secondary endpoints were non-inferiority 
of HFNT to NIV in reducing  PaCO2 at 6 h in the per-protocol and intention-to-treat analysis and rate of treatment 
changes.
Results: Seventy-nine patients were analyzed (80 patients randomized). Mean differences for  PaCO2 reduction from 
baseline to 2 h were − 6.8 mmHg (± 8.7) in the HFNT and − 9.5 mmHg (± 8.5) in the NIV group (p = 0.404). By 6 h, 
32% of patients (13 out of 40) in the HFNT group switched to NIV and one to invasive ventilation. HFNT was statisti-
cally non-inferior to NIV since the 95% confidence interval (CI) upper boundary of absolute difference in mean  PaCO2 
reduction did not reach the non-inferiority margin of 10 mmHg (absolute difference 2.7 mmHg; 1-sided 95% CI 6.1; 
p = 0.0003). Both treatments had a significant effect on  PaCO2 reductions over time, and trends were similar between 
groups. Similar results were found in both per-protocol at 6 h and intention-to-treat analysis.
Conclusions: HFNT was statistically non-inferior to NIV as initial ventilatory support in decreasing  PaCO2 after 2 h of 
treatment in patients with mild-to-moderate AECOPD, considering a non-inferiority margin of 10 mmHg. However, 
32% of patients receiving HFNT required NIV by 6 h. Further trials with superiority design should evaluate efficacy 
toward stronger patient-related outcomes and safety of HFNT in AECOPD.
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Introduction
Chronic obstructive pulmonary disease (COPD) patients 
may require respiratory support and hospitalization due 
to an acute exacerbation of their disease (AECOPD) [1, 
2]. To date, noninvasive ventilation (NIV) represents the 
cornerstone treatment for the management of patients 
with AECOPD with associated respiratory acidosis [3]. 
However, several factors may determine NIV failure like 
discomfort related to the interface, patient–ventilator 
interaction, airway secretions, the severity of the disease, 
and the skill of the team of caregivers [4–7].
High flow nasal therapy (HFNT) [8] has been shown to 
provide potential beneficial effects for patients with sta-
ble COPD: It creates a distending pressure generating a 
positive end-expiratory pressure (PEEP) effect that may 
counterbalance intrinsic PEEP [9], a washout of naso-
pharyngeal dead space optimizing ventilatory efficiency 
and facilitating carbon dioxide removal [10], a reduced 
inspiratory resistance providing adequate flow and warm 
gases preventing bronchoconstriction response to dry air 
[11, 12] enhancing lung mucociliary clearance [13, 14], 
and finally decreasing diaphragmatic effort in a similar 
way to NIV [15]. Recent data also showed that HFNT 
might have a role in managing patients with AECOPD 
[16]. It has been shown to reduce arterial partial pres-
sure of carbon dioxide  (PaCO2) [17, 18] and to improve 
inspiratory effort when used in the NIV interval periods 
as compared to conventional oxygen therapy [19, 20]. 
In non-randomized trials, HFNT showed to be equiva-
lent to NIV in avoiding intubation in mild-to-moderate 
AECOPD patients with respiratory acidosis with similar 
failure rates, but with better comfort and fewer complica-
tions for the patients using HFNT [21, 22]. Thus, there is 
a reasonable physiological and clinical rationale for using 
HFNT in AECOPD, but its efficacy and safety are unclear 
[23].
Our aim was to evaluate the short-term effect of HFNT 
versus NIV in patients with mild-to-moderate AECOPD, 
with the hypothesis that HFNT is non-inferior to NIV on 
 CO2 clearance after 2 h of treatment.
Methods
Study design and patients
This was an investigator-initiated randomized, unblinded, 
multicenter, non-inferiority, controlled trial conducted 
from February 15, 2018, to March 25, 2020. The study 
was conducted in the Emergency Department, Intensive 
Care Units (ICU), or Respiratory Unit of 9 centers in 
Italy. The study protocol was approved by “Comitato 
Etico Sezione Area Centro” Ethics Committee (approval 
no. 245—October 24, 2017, Catanzaro, Italy) and by the 
local ethics committee of all the study centers. This study 
was conducted in accordance with the amended Declara-
tion of Helsinki. Written informed consent was obtained 
from all patients or legal representatives. The study has 
been prospectively registered in ClinicalTrials.gov in 
December 2017 (Identifier: NCT03370666), and the 
study protocol has been published [24].
We considered eligible adults (i.e., > 18  years/old) 
patients with a diagnosis of COPD exacerbation accord-
ing to GOLD criteria [25] admitted for a mild-to-moder-
ate acute hypercapnic respiratory failure, with an arterial 
pH between 7.25 and 7.35 and a  PaCO2 ≥ 55  mmHg. 
Exclusion criteria were: (1) received HFNT or NIV before 
the study enrolment; (2) long-term domiciliary NIV; 
(3) clinical cardiovascular instability, as defined by the 
need for vasopressors, acute coronary syndrome or life-
threatening arrhythmias [26]; (4) treatment refusal; 5) 
agitation, characterized by a Richmond Agitation Seda-
tion Scale (RASS) ≥ 2 or lack of collaboration, defined by 
a Kelly Matthay score ≥ 5 [26]; (6) acute failure of more 
than two organs [26]; (7) cardiac arrest; (8) respiratory 
arrest deeming immediate intubation; (9) recent facial or 
neck trauma, burns or skin breakdown; (10) pregnancy; 
(11) consent withdrawal; and (12) enrolment in other 
research protocols.
Interventions
In the intervention group, patients received HFNT (Opti-
flow and MR850 or AIRVO™ 2, Fisher & Paykel Health-
care, Auckland, New Zealand), initially set at 60 L/min, at 
a temperature of 37 °C. In case of discomfort, flow and/or 
temperature were down-regulated to the most tolerated 
setting.
In the control group, patients received NIV through 
a total full-face or oro-nasal mask. The ventilator was 
set in Pressure Support Ventilation (PSV) mode, with a 
PEEP titrated between 3 and 5 cm  H2O. The inspiratory 
pressure was titrated to achieve a measured or estimated 
expiratory tidal volume equal to 6–8  mL  kg−1 of ideal 
body weight [26]. The attending physician, based on local 
availability, selected the ventilators used to deliver NIV.
In both groups, therapeutic management other than 
ventilatory support was according to current guidelines 
Trial registration: The study was prospectively registered on December 12, 2017, in ClinicalTrials.gov (NCT03370666).
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[25]. Sedation was allowed to improve patients’ comfort 
and tolerance of the interfaces (target RASS between 
0 and -2). The inspired oxygen fraction  (FiO2) was set 
to maintain a peripheral oxygen saturation  (SpO2) tar-
get between 88–92% [25]. During study interventions, 
patients were monitored with continuous  SpO2, electro-
cardiogram, and noninvasive blood pressure.
Study endpoints
The primary endpoint was the mean difference of  PaCO2 
to evaluate the non-inferiority of HFNT to NIV from 
baseline to 2  h after the randomization. The secondary 
endpoints were: (1) non-inferiority of HFNT to NIV in 
reducing  PaCO2 at 6 h after randomization; (2) treatment 
change rates (switch to the other study intervention, to 
IMV, to no support or no change); (3) dyspnea score and 
proportion of patients who did not improve the dyspnea 
score; (4) discomfort score and proportion of patients 
showing poor tolerance to treatment; (5) the propor-
tion of patients who had  PaCO2 worsening or reduc-
tion < 10 mmHg from baseline assessment, or worsening 
or no improvement of the dyspnea; (6) respiratory rate; 
(7) change in arterial blood gases; 8) time spent under 
mechanical ventilation (both IMV and NIV); (9) hospital 
length of stay; and (10) hospital mortality.
Data collection and outcome assessment
We collected anthropometric and clinical baseline char-
acteristics, i.e., the Simplified Acute Physiology Score 
(SAPS II), the Kelly-Matthay Score [27], the Charlson 
index [28], and the Richmond Agitation Sedation Scale 
(RASS) [29]. Furthermore, soon before the randomiza-
tion, we collected the vital parameters, the presence of 
dyspnea (Borg scale) [30], and the arterial blood gases 
at patients’ inclusion. All these relevant variables and 
endpoints were evaluated at 2 and 6 h after randomiza-
tion. In particular, we recorded: the NIV and HFNT set-
tings; the discomfort related to the interface, as assessed 
through a ten-point numeric rating scale [31], the pro-
portion of patients reporting poor tolerance to the treat-
ment (defined as a patient-reported complaint to the 
assigned treatment that did not cause treatment inter-
ruption) due to flow, temperature, noise, claustrophobia, 
sweating, tightness, airway dryness, vomiting gastric dis-
tension, ocular irritation, or skin breakdown [31].
The decision to change the assigned treatment was 
left up to the clinical judgment of the attending physi-
cian and was motivated (in unfavorable cases) by any 
of the following: failure to improve or worsening of 
clinical signs of respiratory failure or gas exchange (i.e., 
 PaCO2 > 20% baseline and/or pH < 7.25) in the case of 
change from HFNT to NIV; intolerance to the assigned 
intervention defined as a patient-reported complaint that 
compromised the pursuit of the treatment (i.e., subject 
refusal). The decision to intubate was based on the phy-
sician’s clinical judgment and on the presence of at least 
one of the following criteria: respiratory arrest, respira-
tory apnea or pauses with loss of consciousness, severe 
agitation, bradycardia (< 50 beats/min) with loss of con-
sciousness, hemodynamic instability with systolic arterial 
pressure < 70  mmHg, need for invasive mechanical ven-
tilation due to worsening in arterial blood gases and pH 
decline or pH < 7.25, management of abundant respira-
tory secretions, intolerance to all the interfaces (includ-
ing the eventual change of the treatment). Data were 
collected on a dedicated case report form.
Randomization and statistical analysis
We computed a sample size of 56 patients, given an alpha 
error of 5% (one-sided) and a power of 80%, with a stand-
ard deviation for the primary outcome equal to 15 mmHg 
and a non-inferiority limit of 10 mmHg. Thus, the non-
inferiority would be demonstrated if the upper bound-
ary of the 95% CI for the mean difference was lower than 
10  mmHg. A non-inferiority margin of 10  mmHg was 
set as a clinically relevant difference in change of  PaCO2 
between the groups by consensus among the investiga-
tors, based on clinical judgment and available data at 
the time of trial design [17, 26, 32, 33]. After consider-
ing potential dropouts (30%) and an increase in sample 
size for nonparametric analysis (15%), the final computed 
sample size was 80 patients (40 per group). No imputa-
tion was planned for missing data.
Randomization was achieved using a computer-gen-
erated randomization sequence, generated by an inde-
pendent investigator, not otherwise involved in the trial, 
with an allocation ratio of 1:1 and with permuted block 
method. A single randomization list for all participants 
was created. Allocation concealment was maintained 
using sequentially numbered sealed opaque envelopes. 
Each envelope contained the patient’s allocation to either 
control (NIV) or intervention (HFNT), with a unique 
patient identifier code. The randomization was based 
on a centralized phone call system. Due to the research 
design, neither the individual collecting data nor the 
patient can be blinded to treatment allocation. The base-
line was defined as the time of randomization.
An independent statistician (FM), blinded to treat-
ment allocation, performed all statistical analyses on per-
protocol and intention-to-treat bases as recommended 
[34]. The per-protocol analysis included only patients 
who received the randomly assigned intervention till 
the 2-h (per-protocol analysis at 2 h) and the 6-h assess-
ment (per-protocol analysis at 6 h), excluding those who 
changed the treatment. The intention-to-treat analysis 
included all patients according to the randomization, 
Page 4 of 13Cortegiani et al. Crit Care          (2020) 24:692 
whether they changed the intervention or not at the 
study timepoints [34].
After checking the skewness of distribution, continu-
ous data will be presented as mean (standard devia-
tion) or median [25th–75th percentile]. Categorical data 
were expressed as counts and percentages. Differences 
between treatments in continuous variables were evalu-
ated by the Mann–Whitney U-test or the Student t test 
according to Normal distribution. Categorical data were 
compared with the Chi-square test or Fisher exact test. 
Paired sample t test or paired samples Wilcoxon test were 
used to assess the difference between timepoints in con-
tinuous variables for each group. Change over time was 
modeled using mixed-effects linear regression with a ran-
dom intercept and slope (time) in order to account for 
non-independence among measures.  PaCO2 values were 
regressed on time (baseline, 2  h, 6  h), group treatment 
(HFNT, NIV), and the time per group interaction.
For the primary outcome, a one-sided two-sample 
Student t test was performed while taking into account 
the non-inferiority margin (10  mmHg) to test whether 
 PaCO2 reduction with HFNT was non-inferior to NIV. 
The same approach was used to evaluate the non-inferi-
ority of HFNT compare to NIV in the  PaCO2 decrease 
after 6 h.
A p value < 0.05 will be considered significant. Statisti-
cal analyses were performed with SAS software, version 
9.4 (SAS Institute Inc., Cary, NC, USA) and R, version 
3.5.2 (The R Foundation for Statistical Computing) was 
used for data visualization. Data monitoring was done 
by two investigators (LB, PC) querying the final database 
after collecting CRFs from enrolling centers.
Results
CONSORT checklist for this non-inferiority trial is 
reported in the Additional file 1.
Patients and interventions
From 235 eligible patients, we randomized 80 patients, 
40 in both groups (Fig. 1). The most frequent reason for 
exclusion that we registered was the prior use of NIV 
or HFNT before enrollment (53 out of 155 patients 
excluded). One patient withdrew consent after randomi-
zation; therefore, data from 79 patients was analyzed.
Baseline characteristics and blood gases of patients 
were evenly distributed between the two groups 
(Table  1). Mean age was 74 (± 13) and 77 (± 12), SAPS 
II was 30 (± 9.0), and 33 (± 10), the mean arterial pH 
was 7.30 (± 0.03) and 7.29 (± 0.03), and the mean  PaCO2 
was 73.7 mmHg (± 12.8) and 72.0 mmHg (± 13.0) in the 
HFNT and NIV group, respectively (Table 1).
All patients received the assigned treatment after ran-
domization. By 2 h, six patients in the HFNT group had 
switched to NIV (n = 5 worsening/no improvement of 
respiratory failure; n = 1 intolerance to the intervention) 
while one patient switched to HFNT (intolerance to the 
intervention) and one to IMV in the NIV group (wors-
ening of respiratory failure). By 6  h, seven patients had 
switched to NIV (worsening/no improvement of res-
piratory failure), one to IMV (worsening of respiratory 
failure) in the HFNT group. Due to the improvement of 
respiratory failure, one patient switched to no support in 
the HFNT group while two patients switched to HFNT 
and six to no support in the NIV group.
Seventy-one patients (HFNT n = 34 [85%] vs. NIV 
n = 37 [95%]; p = 0.2633) and 53 patients (HFNT n = 24 
[60%] vs. NIV n = 29 [74.4%]; p = 0.1745) continued 
the allocated interventions after 2 and 6  h, respectively 
(Fig.  1, Table  2). Characteristics of interventions are 
reported in Additional file  2: Table  S1. During the 6  h 
of treatment, three patients in the HFNT (7.5%) and in 
the NIV (7.7%) received sedatives according to the study 
protocol.
Per‑protocol analysis
At baseline, clinical characteristics and blood gases 
were similar between the two groups in patients who 
completed the treatment initially allocated after 2  h 
(see Additional file  2: Table  S2). Mean differences for 
 PaCO2 from baseline to 2  h were − 6.8  mmHg (± 8.7) 
in the HFNT and − 9.5 mmHg (± 8.5) in the NIV group 
(p = 0.404) (Table  3). Figure  2a, b shows the differences 
and trends in  PaCO2. Both treatments were able to sig-
nificantly lower the  PaCO2 over the study timepoints 
(Fig.  2a). As regards to the primary outcome, absolute 
 PaCO2 difference was 2.7 mmHg (1-sided 95% CI − ∞; 
6.1) and HFNT was non-inferior to NIV since the upper 
boundary of 95% CI did not reach the non-inferiority 
margin of 10 mmHg (p = 0.0003, Fig. 3). Both treatments 
had a significant effect on  PaCO2 reduction over time 
(time effect, p < 0.0001), and trends were similar between 
groups (interaction term, p = 0.5864), (Fig. 2b).
Similar results were found in the per-protocol analysis 
at 6 h (see Fig. 2c, d; Table 3, Additional file 2: Table S3 
and Figure S1). However, in this analysis, there was a 
lower baseline SAPS II score in the HFNT group.
Intention‑to‑treat analysis and secondary outcomes
In Additional file 2: Figure S2 (panel A and B) shows the 
differences and trends in  PaCO2 for this analysis. Both 
interventions significantly lower  PaCO2 over the study 
timepoints in both groups. Criteria for the non-inferior-
ity of HFNT versus NIV were also met in this analysis at 
2 and 6 h (Fig. 3, Additional file 2: Figure S1)
The other secondary outcomes, including dyspnea 
score, discomfort, length of mechanical ventilation, 
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Fig. 1 Flow diagram of the trial according to CONSORT
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respiratory rate, the proportion of patients with wors-
ening or no significant reduction in  PaCO2 values after 
6  h, length of hospital stay, and hospital mortality are 
reported in Table 2.
A higher proportion of patients in the NIV group 
showed poor tolerance to the intervention by 6 h (74%) 
compare to HFNT (35%) (p = 0.0019). The discomfort 
score was slightly higher in the NIV group at 2 and 6 h of 
Table 1 Patients’ characteristics in  the  high flow nasal therapy (HFNT) and  noninvasive ventilation (NIV) groups 
at baseline
BMI body mass index, FiO2 fraction of inspired oxygen, HCO3
− bicarbonate, HFNT high-flow nasal therapy, ICU intensive care unit, IQR interquartile range (first and third 
quartile), NIV noninvasive ventilation, PaO2arterial partial pressure, PaCO2 partial pressure of carbon dioxide, RASS Richmond agitation-sedation scale, SAPS simplified 
acute physiology score, SD standard deviation
a Data was not available for five patients (three in HFNT and two NIV group)
b Data was not available for one patient in NIV group
c Data was not available for one patient in HFNT group
HFNT group NIV group p value
N 40 39
Females, n (%) 19 (47.5) 20 (51.3) 0.7368
Age (years), mean ± SD 74 ± 13 77. ± 12 0.2273
Weight (kg)a, mean ± SD 85 ± 23 76 ± 13 0.0964
Height (m)a, mean ± SD 1.7 ± 0.1 1.7 ± 0.1 0.5494
BMI (kg/m2)a, mean ± SD 30.5 ± 8.7 26.7 ± 5.5 0.0622
Ward of admission, n (%) 0.5807
 Emergency room 24 (60) 21 (53.8)
 ICU or respiratory unit 16 (40) 18 (46.1)
SAPS II, mean ± SD 30 ± 9 33 ± 10 0.1497
Charlson index, mean ± SD 4 ± 2 5 ± 3 0.4709
Systolic blood pressure (mmHg), mean ± SD 131 ± 27 137 ± 24 0.3629
Diastolic blood pressure (mmHg), mean ± SD 71 ± 17 70 ± 13 0.7089
Heart rate (per min), mean ± SD 91 ± 20 92 ± 19 0.9609
Respiratory rate (per min), mean ± SD 27 ± 7 28 ± 7 0.5544
Body  temperatureb (C°), mean ± SD 36.6 ± 0.7 36.8 ± 0.5 0.0489
Kelly Matthay score, n (%) 0.0694
 Alert, follows complex command (1) 19 (47.5) 25 (64.1)
 Alert, follows simple commands (2) 9 (22.5) 8 (20.5)
 Lethargie (3) 12 (30) 4 (10.3)
 Stuporous (4) 0 (0) 2 (5.1)
Borg dyspnea  scoreb, mean ± SD 5 ± 2 5 ± 2 0.4463
RASS, n (%) 0.4813
 Light sedation (− 2) 2 (5) 2 (5.1)
 Drowsy (− 1) 13 (32.5) 7 (17.9)
 Alert and calm (0) 21 (52.5) 26 (66.7)
 Restless (+ 1) 4 (10) 4 (10.3)
Secretion, n (%) 0.2163
 Normal 23 (57.5) 17 (43.6)
 Abundant 17 (42.5) 22 (56.4)
PaCO2 (mmHg), mean ± SD 73.7 ± 12.8 72.0 ± 13.0 0.5270
Arterial pH, mean ± SD 7.30 ± 0.03 7.29 ± 0.03 0.7450
PaO2 (mmHg), mean ± SD 64.3 ± 17.6 73.3 ± 27.9 0.1480
SpO2 (%), median [IQR] 90.1 [87.0–94.1] 92.0 [88.0–96.0] 0.1835
HCO3
− (mmol  L−1), mean ± SD 34.3 ± 5.9 33.1 ± 6.30 0.3680
PaO2/FiO2, mean ± SD 203.2 ± 45.5 222.4 ± 71.0 0.4801
Lactatec (mmol  L−1), median [IQR] 1.1 [0.7–1.6] 1.1 [0.9–1.5] 0.7376
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treatment. For the other secondary outcomes, no differ-
ences were found between groups.
Changes in arterial blood gases and vital param-
eters over the study timepoints for the per-protocol 
analysis and intention-to-treat analysis were reported 
in Additional file  2: Tables S4–S6. We found no dif-
ference in mean change in arterial pH from base-
line to 2  h (HFNT group: 0.04 ± 0.04, NIV group: 
0.05 ± 0.03, p = 0.39) in the per-protocol analysis at 
2 h. In the same analysis, we found a significant differ-
ence in mean change of  PaO2/FiO2 ratio (HFNT group: 
Table 2 Clinical outcomes in the high flow nasal therapy (HFNT) and noninvasive ventilation (NIV) groups
HFNT high flow nasal therapy, IQR interquartile range [first and third quartile], IMV invasive mechanical ventilation, NIV noninvasive ventilation
a Poor tolerance was defined as patient-reported complaint to the assigned treatment that did not cause treatment interruption. Intolerance was defined as patient-
reported complaint that compromised the pursuit of the treatment (i.e., subject refusal)
b Outcome evaluated on patients still receiving the assigned treatment at 2 h (34 HFNT, 37 NIV)
c Outcome evaluated on patients still receiving the assigned treatment at 6 h (24 HFNT, 29 NIV)
d IMV during hospitalization was calculated from baseline from hospital discharge or death
HFNT group NIV group p value
N 40 39
Treatment changes from baseline to 2 h, n (%)
 Switching to NIV or HFNT 6 (15) 1 (2.6) 0.1084
 IMV 0 (0 1 (2.6) 0.4937
 No treatment change 34 (85) 37 (94.9) 0.2633
Treatment changes from baseline to 6 h, n (%)
 Switch to NIV or HFNT 13 (32.5) 3 (7.7) 0.0061
 Switch to IMV 1 (2.5) 1 (2.6) 1.0000
 Switch to no support 2 (5) 6 (15.4) 0.1543
 No treatment change 24 (60) 29 (74.4) 0.1745
Poor treatment tolerance/intolerance from baseline to 6  hoursa, n (%)
 In patients switching to NIV or HFNT or IMV 5 (35.7) 3 (75) 0.2745
 In patients switching to no support or with no treatment change 9 (34.6) 26 (74.3) 0.0019
Discomfort, median [IQR]
 At 2  ha 1 [0–2] 3 [1–5] 0.0010
 At 6  hb 0 [0–2] 2 [1–4] 0.0003
Borg dyspnea score, mean ± SD
 At 2  ha 3 ± 2 3 ± 2 0.2509
 At 6  hb 5 ± 2 5 ± 2 0.4865
No improvement of Borg dyspnea score at 6 h, n (%) 6 (15) 6 (15.4) 0.9620
Respiratory rate (per min), mean ± SD
 At 2  hb 22 ± 5 22 ± 4 0.5789
 At 6  hc 20 ± 4 21 ± 4 0.5573
PaCO2 worsening or reduction < 10 mmHg after 6 h, n (%) 23 (57.5) 14 (35.9) 0.0544
IMV during  hospitalizationd
 Subjects, n (%) 2 (5) 1 (2.6) 1.0000






 Subjects, n (%) 23 (57.5) 39 (100.0)  < .0001





Length of hospital stay (days), median [IQR]
 All patients 10 [9–19] 13 [9–16] 0.6579
 Survivors at hospital discharge 10 [9–19] 13 [9–16] 0.5510
 Dead at hospital discharge 16 [9–22] 15 [3–19] 0.6150
In-hospital mortality, n (%) 2 (5) 6 (15.4) 0.1543
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−16.5 ± 52.2  mmHg, NIV group: 7.2 ± 56.3  mmHg, 
p = 0.0357) (see Additional file 2: Table S4).
Discussion
The main findings of this trial are that HFNT was non-
inferior to NIV as initial ventilatory support in mean 
 PaCO2 reduction in patients with mild-to-moderate 
AECOPD considering a non-inferiority margin of 
10  mmHg; HFNT was able to reduce  PaCO2 over both 
study timepoints significantly, but 32% (14/40) of patients 
were switched to NIV within 6 h.
To the best of our knowledge, this is the first multi-
center randomized controlled non-inferiority trial com-
paring NIV and HFNT in mild-to-moderate AECOPD. 
In our study, we included patients with mild-to-moderate 
AECOPD for two reasons: (1) the efficacy and safety of 
HFNT in AECOPD have not been demonstrated so far 
[16]; (2) NIV is considered the gold standard respiratory 
support for managing patients with AECOPD with high-
quality evidence supporting its use [3]. However, HFNT 
has shown several valuable effects in COPD patients 
[16] and there are some drawbacks of using NIV, such as 
reduced comfort and poor patient–ventilator interaction, 
which is often challenging to recognize and manage [4, 5, 
35]. We intended to determine whether HFNT was not 
inferior to NIV in achieving relevant changes in physi-
ologic outcomes in AECOPD patients (i.e.,  PaCO2) and 
explore its safety as the first step for future superiority 
trials.
Previously published studies had shown the promis-
ing results on the efficacy and safety of HFNT use for 
treating AECOPD. A retrospective study performed in 
a single ICU compared HFNT and NIV in 82 patients 
Table 3 Modifications in  PaCO2 values during follow-up period in study population stratified by intervention (high flow 
nasal therapy and noninvasive ventilation)
HFNT high flow nasal therapy, NIV noninvasive ventilation, PaCO2 partial pressure of carbon dioxide, SD standard deviation, Δ difference in  PaCO2 values between 
timepoints
HFNT group NIV group p value
Per-protocol 2 h
PaCO2 (mmHg) on patients who completed the treatment originally 
allocated at 2 h, mean ± SD
 Subjects, n 34 37 –
 At baseline ( T0) 74.0 ± 13.5 72.2 ± 13.3 0.5845
 After 2 h ( T2h ) 67.2 ± 16.4 62.7 ± 13.5 0.1933
 After 6 h ( T6h ) 64.5 ± 15.8 57.9 ± 12.2 0.0630
 ΔT2h − T0 − 6.8 ± 8.7 − 9.5 ± 8.5 0.4040
 ΔT6h − T0 − 9.5 ± 13.0 − 14.3 ± 11.1 0.0962
 ΔT6h − T2h − 2.7 ± 9.7 − 4.8 ± 7.1 0.1637
Per-protocol 6 h
PaCO2 (mmHg) on patients who completed the treatment originally 
allocated at 6 h, mean ± SD
 Subjects, n 24 29 −
 At baseline ( T0) 72.7 ± 10.3 74.0 ± 13.7 0.7955
 After 2 h ( T2h ) 64.7 ± 8.7 63.7 ± 14.5 0.7493
 After 6 h ( T6h ) 61.4 ± 7.7 59.8 ± 12.6 0.5632
 ΔT2h − T0 − 8.0 ± 6.5 − 10.3 ± 8.9 0.5200
 ΔT6h − T0 − 11.3 ± 7.3 − 14.2 ± 12.0 0.4475
 ΔT6h − T2h − 3.3 ± 6.9 − 3.9 ± 7.6 0.8163
Intention-to-treat analysis
PaCO2 (mmHg) of enrolled patients, mean ± SD
 Subjects, n 40 39
 At baseline ( T0) 73.7 ± 12.8 72.0 ± 13.0 0.5270
 After 2 h ( T2h ) 68.2 ± 15.6 63.4 ± 13.6 0.1387
 After 6 h ( T6h ) 64.0 ± 14.9 58.1 ± 12.4 0.0610
 ΔT2h − T0 − 5.5 ± 9.3 − 8.6 ± 9.3 0.2940
 ΔT6h − T0 − 9.7 ± 13.2 − 13.9 ± 11.3 0.1329
 ΔT6h − T2h − 4.2 ± 11.1 − 5.3 ± 7.5 0.3670
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with mild-to-moderate AECOPD. No difference was 
found in the proportion of patients who switched 
treatment or received IMV (28% HFNT vs. 39% NIV). 
Of note, patients were assigned to study treatments 
if they received HFNT or NIV for at least 4  h within 
the first 24 h from admission [22]. In an observational 
study performed in one respiratory unit, no difference 
was found between HFNT and NIV with regard to the 
30-day intubation rate (25% vs. 27%) and mortality rate 
(16% vs. 18%) in 92 patients with moderate AECOPD. 
The investigators also compared blood gases (including 
 PaCO2) at 6- and 24-h, finding no difference between 
groups [21]. The results included between-group analy-
sis at each timepoint, and no comparison of trends or 
differences were reported. A randomized study per-
formed in one respiratory unit concluded that HFNT 
Fig. 2 a, c Report boxplots showing median, interquartile range and mean (full dot) for  PaCO2 differences (ΔPaCO2) between baseline (T0), 2 h (T2h) 
and 6 h (T6h) in HFNT and NIV groups (*p value < 0.05, difference ≠ 0) in per-protocol analysis at 2 h and at 6 h, respectively; b, d report mean  PaCO2 
(and 95% confidence interval) observed at T0, T2h, T6h in HFNT and NIV groups in per-protocol analysis at 2 h and at 6 h, respectively
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and NIV were both effective in improving blood gases 
in 168 patients with AECOPD and the HFNT group 
had a lower rate of complications and higher comfort. 
No sample size calculation and protocol registration 
have been reported and the outcomes assessment was 
done after 12 h and 5 days [36].
We showed that HFNT might be a feasible initial ven-
tilator strategy in the management of mild-to-moderate 
AECOPD, finding a mean difference in  PaCO2 reduction 
of 2.66 mmHg at 2 h, and the 95% CI upper boundary of 
absolute difference in mean  PaCO2 reduction not reach-
ing the set non-inferiority margin of 10  mmHg. Never-
theless, we acknowledge that a different non-inferiority 
margin and a larger sample size would have changed the 
study conclusions. From a clinical point of view, a cli-
nician may prefer a technique allowing a greater and 
faster decarboxylation. In fact, 32% of patients treated 
with HFNT were switched to NIV, even if patients had 
a slightly lower severity of illness (SAPS II) than those in 
the NIV group (Table 1 and Additional file 2). Moreover, 
in our study cohort, patients randomized to HFNT wors-
ened the oxygenation during the 6  h (Additional file  2: 
Table  S4), and those who subsequently underwent NIV 
during hospitalization had a longer length of NIV than 
those originally allocated to the NIV group (Table  2). 
Altogether, these findings should incite caution in declar-
ing that HFNT is non-inferior to NIV from a clinical 
perspective, all the most because NIV is a true standard 
of care in this context.
The external validity of our findings is supported by 
the multicenter design, but the results may have changed 
according to different expertise in the use of devices, set-
tings and management protocols of AECOPD. Of note, 
all patients were continuously monitored with standard 
tools and serial blood gases check, so our findings can-
not be extrapolated to settings with different levels of 
care. Larger clinical trials comparing HFNT and NIV 
in this patient population are currently ongoing, focus-
ing on other outcomes such as endotracheal intubation 
(NCT03014869) and treatment failure (NCT03466385) 
or with crossover design (NCT03033251).
Strengths of the study were the multicenter rand-
omized design, the prospective registration, and pro-
tocol publication and the analyses, both per-protocol 
and intention-to-treat, according to CONSORT rec-
ommendations for non-inferiority trials. However, our 
study has limitations. First, due to the nature of the 
interventions, blinding was not possible. This study was 
a non-inferiority trial with a primary physiologic out-
come, leaving uncertainty on stronger patient-related 
outcomes. Moreover, due to the study design, the vari-
ables associated with the need for escalation of treat-
ments cannot be adequately evaluated. Although we 
found lower baseline oxygenation in HFNT patients 
Fig. 3 Absolute difference between HFNT and NIV treatment in mean  PaCO2 reduction after 2 h (and 1-sided 95% confidence interval), according 
to conducted analyses: per-protocol on patients who completed the treatment originally allocated after 2 h (PP 2 h) and intention-to-treat (ITT). The 
black box indicates the mean  PaCO2 reduction after 2 h, full lines indicate 95% confidence interval and dashed line the pre-planned non-inferiority 
margin of 10 mmHg
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who escalated the treatment to NIV or IMV after 6  h 
compared to patients who did not switch (see Addi-
tional file  2: Table  S7), further studies should assess 
predictors for HFTN success in this patient population. 
Our patient cohort was old and the mean BMI in the 
HFNT group was 30  kg/m2 (± 8.7). These factors may 
limit the external validity of our findings. Furthermore, 
we cannot exclude the co-presence of obesity-related 
hypoventilation. It is difficult to screen patients for this 
condition during the first management AECOPD, but 
we excluded patients on domiciliary NIV. We did not 
register the tidal volume generated or estimated by the 
ventilators in the NIV group. Thus, we cannot exclude 
that the applied level of pressure support might have 
affected patients’ comfort and NIV tolerance. Moreo-
ver, the PEEP values applied were slightly higher than 
the range stated in the protocol.
Our study had a parallel-group design with short-term 
timepoints of assessment, so we cannot evaluate the effi-
cacy and safety of sequential use of the study treatments. 
The findings that 32% of patients after 6 h and more than 
50% of patients during hospitalization needed NIV sug-
gest that the two treatments may have a complementary 
role in AECOPD that should be further studied [19]. We 
collected data about the primary outcome, blood gases 
and secondary outcomes at 6 h as the longest follow-up 
without further assessments. This can limit the evalu-
ation of the long-term efficacy of HFNT. However, we 
registered patients’ safety-related outcomes until hospital 
discharge or death.
At 6 h, the number of patients actually treated as ran-
domly allocated was slightly lower (n = 53) than the cal-
culated sample size (n = 56) for the primary outcome at 
2 h. The power of our per-protocol analysis after 6 h was 
76.5%, and therefore, the estimate of the compared effect 
at this timepoint should be considered with caution. 
Finally, it has to take into account also the documented 
clinical heterogeneity of COPD exacerbations [37]; there-
fore, although we used strict criteria to define mild-to-
moderate AECOPD, we may have enrolled patients with 
different trajectories of the diseases and responses to 
ventilator support and medical treatments.
Conclusions
In this trial, HFNT was statistically non-inferior to 
NIV as initial ventilatory support in decreasing  PaCO2 
after 2  h of treatment in patients with mild-to-moder-
ate AECOPD, considering a non-inferiority margin of 
10  mmHg. However, 32% of patients receiving HFNT 
required NIV by 6  h. Further trials with superiority 
design should evaluate efficacy toward stronger patient-
related outcomes and safety of HFNT in AECOPD.
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